|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forouzanfar MH, Foreman KJ, Delossantos
AM, et al: Breast and cervical cancer in 187 countries between 1980
and 2010: a systematic analysis. Lancet. 378:1461–1484. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Figueroa-Vallés NR, Ortiz-Ortiz KJ,
Pérez-Ríos N, Villanueva-Rosa E, Traverso-Ortiz M, Torres-Cintrón
CR and Suárez-Ramos T: Cancer in Puerto Rico, 2004–2009. Puerto
Rico Central Cancer Registry; San Juan: 2012
|
|
5
|
Gøtzsche PC: Mammography screening: truth,
lies, and controversy. Lancet. 380:2182012.PubMed/NCBI
|
|
6
|
Ogino S, Lochhead P, Chan AT, et al:
Molecular pathological epidemiology of epigenetics: emerging
integrative science to analyze environment, host, and disease. Mod
Pathol. 26:465–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ostrow KL, Park HL, Hoque MO, et al:
Pharmacologic unmasking of epigenetically silenced genes in breast
cancer. Clin Cancer Res. 15:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim GE, Lee KH, Choi YD, et al: Detection
of Slit2 promoter hypermethylation in tissue and serum samples from
breast cancer patients. Virchows Arch. 459:383–390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramos JM, Ruiz A, Colen R, Lopez ID,
Grossman L and Matta JL: DNA repair and breast carcinoma
susceptibility in women. Cancer. 100:1352–1357. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matta JL, Villa JL, Ramos JM, et al: DNA
repair and nonmelanoma skin cancer in Puerto Rican populations. J
Am Acad Dermatol. 49:433–439. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matta J, Echenique M, Negron E, et al: The
association of DNA repair with breast cancer risk in women. A
comparative observational study. BMC Cancer. 12:4902012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morales L, Alvarez-Garriga C, Matta J, et
al: Factors associated with breast cancer in Puerto Rican women. J
Epidemiol Glob Health. 3:205–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoque MO, Begum S, Topaloglu O, et al:
Quantitation of promoter methylation of multiple genes in urine DNA
and bladder cancer detection. J Natl Cancer Inst. 98:996–1004.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosner B: Fundamentals of Biostatistics.
7th edition. Brooks/Cole; Boston, MA: 2010
|
|
15
|
Szklo MNJ: Epidemiology Beyond the Basics.
Jones and Bartlett Learning; Burlington, MA: 2006
|
|
16
|
Lo KY, Kuzmin A, Unger SM, Petersen JD and
Silverman MA: KIF1A is the primary anterograde motor protein
required for the axonal transport of dense-core vesicles in
cultured hippocampal neurons. Neurosci Lett. 491:168–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Brait M, Loyo M, Rosenbaum E, et al:
Correlation between BRAF mutation and promoter methylation
of TIMP3, RARβ2 and RASSF1A in thyroid cancer.
Epigenetics. 7:710–719. 2012.
|
|
18
|
Roh JL, Wang XV, Manola J, Sidransky D,
Forastiere AA and Koch WM: Clinical correlates of promoter
hypermethylation of four target genes in head and neck cancer: a
cooperative group correlative study. Clin Cancer Res. 19:2528–2540.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ostrow KL, Hoque MO, Loyo M, et al:
Molecular analysis of plasma DNA for the early detection of lung
cancer by quantitative methylation-specific PCR. Clin Cancer Res.
16:3463–3472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demokan S, Chang X, Chuang A, et al: KIF1A
and EDNRB are differentially methylated in primary HNSCC and
salivary rinses. Int J Cancer. 127:2351–2359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De S, Cipriano R, Jackson MW and Stark GR:
Overexpression of kinesins mediates docetaxel resistance in breast
cancer cells. Cancer Res. 69:8035–8042. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Horne HN, Lee PS, Murphy SK, Alonso MA,
Olson JA Jr and Marks JR: Inactivation of the MAL gene in
breast cancer is a common event that predicts benefit from adjuvant
chemotherapy. Mol Cancer Res. 7:199–209. 2009.
|
|
23
|
Suzuki M, Shiraishi K, Eguchi A, et al:
Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small
cell lung cancer. Oncol Rep. 29:1308–1314. 2013.PubMed/NCBI
|
|
24
|
Lind GE, Danielsen SA, Ahlquist T, et al:
Identification of an epigenetic biomarker panel with high
sensitivity and specificity for colorectal cancer and adenomas. Mol
Cancer. 10:852011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galigniana MD, Harrell JM, O‘Hagen HM,
Ljungman M and Pratt WB: Hsp90-binding immunophilins link p53 to
dynein during p53 transport to the nucleus. J Biol Chem.
279:22483–22489. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin JF, Xu J, Tian HY, et al:
Identification of candidate prostate cancer biomarkers in prostate
needle biopsy specimens using proteomic analysis. Int J Cancer.
121:2596–2605. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ward BK, Mark PJ, Ingram DM, Minchin RF
and Ratajczak T: Expression of the estrogen receptor-associated
immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast
Cancer Res Treat. 58:267–280. 1999.PubMed/NCBI
|
|
28
|
Levi A, Ferri GL, Watson E, Possenti R and
Salton SR: Processing, distribution, and function of VGF, a
neuronal and endocrine peptide precursor. Cell Mol Neurobiol.
24:517–533. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferri GL, Noli B, Brancia C, D‘Amato F and
Cocco C: VGF: an inducible gene product, precursor of a diverse
array of neuro-endocrine peptides and tissue-specific disease
biomarkers. J Chem Neuroanat. 42:249–261. 2011. View Article : Google Scholar
|
|
30
|
Brait M, Maldonado L, Noordhuis MG, et al:
Association of promoter methylation of VGF and PGP9.5
with ovarian cancer progression. PLoS One. 8:e708782013.PubMed/NCBI
|
|
31
|
Brait M, Maldonado L, Begum S, et al: DNA
methylation profiles delineate epigenetic heterogeneity in seminoma
and non-seminoma. Br J Cancer. 106:414–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sen T, Sen N, Noordhuis MG, et al: OGDHL
is a modifier of AKT-dependent signaling and NF-κB function. PLoS
One. 7:e487702012.PubMed/NCBI
|
|
33
|
Lahtz C and Pfeifer GP: Epigenetic changes
of DNA repair genes in cancer. J Mol Cell Biol. 3:51–58. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leary AF, Castro DG, Nicholson AG, et al:
Establishing an EGFR mutation screening service for
non-small cell lung cancer - sample quality criteria and candidate
histological predictors. Eur J Cancer. 48:61–67. 2012.
|
|
35
|
Silva JM, Dominguez G, Garcia JM, et al:
Presence of tumor DNA in plasma of breast cancer patients:
clinicopathological correlations. Cancer Res. 59:3251–3256.
1999.PubMed/NCBI
|
|
36
|
Hoque MO, Feng Q, Toure P, et al:
Detection of aberrant methylation of four genes in plasma DNA for
the detection of breast cancer. J Clin Oncol. 24:4262–4269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heichman KA and Warren JD: DNA methylation
biomarkers and their utility for solid cancer diagnostics. Clin
Chem Lab Med. 50:1707–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Latimer JJ, Johnson JM, Kelly CM, et al:
Nucleotide excision repair deficiency is intrinsic in sporadic
stage I breast cancer. Proc Natl Acad Sci USA. 107:21725–21730.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li L: Nucleotide excision repair. DNA
Repair, Genetic Instability and Cancer. Wei Q, Lei L and Chen DJ:
World Scientific; Singapore: pp. 65–86. 2007, View Article : Google Scholar
|
|
40
|
Berwick M and Vineis P: Measuring DNA
repair capacity: small steps. J Natl Cancer Inst. 97:84–85. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Curtin N: PARP inhibitors for anticancer
therapy. Biochem Soc Trans. 42:82–88. 2014. View Article : Google Scholar
|
|
42
|
Eccles SA, Aboagye EO, Ali S, et al:
Critical research gaps and translational priorities for the
successful prevention and treatment of breast cancer. Breast Cancer
Res. 15:R922013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Glendenning J and Tutt A: PARP inhibitors
- current status and the walk towards early breast cancer. Breast.
20(Suppl 3): S12–S19. 2011. View Article : Google Scholar : PubMed/NCBI
|
